This is a cpff to to refurbish APA buildings (1033).
Active Awarded Last action
- Contract number
- 75N91022F00030
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,232,704
Award facts
- Contract value 100% obligated
- $6,232,704.00 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$200,410 | |
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $713,518 | |
| Other Administrative Action | $0 | |
| Original award | $5,719,596 |
About this award
Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc. and Federally Funded Research and Development Center (FFRDC) contractor, was awarded a Cost Plus Fixed Fee delivery order valued at $6.23 million by the National Cancer Institute to refurbish APA buildings at the Frederick, Maryland location. The contract, awarded on September 23, 2022, with an ultimate completion date of February 5, 2027, carries no set-aside designation and reflects the National Cancer Institute's infrastructure modernization efforts. This delivery order is part of broader government efficiency initiatives focused on optimizing facility management and capital improvements.
As a specialized biomedical research support contractor serving the National Cancer Institute and National Institutes of Health, Leidos Biomedical Research Inc. brings extensive experience in facilities infrastructure improvements and project management. The refurbishment work supports the Frederick National Laboratory for Cancer Research's operational capabilities and represents a continuation of the company's long-standing role in managing and enhancing federal research facilities. The contract duration of approximately four and a half years indicates a comprehensive renovation scope designed to maintain and upgrade critical infrastructure supporting the National Cancer Institute's research mission.
Quick answers
Who was awarded contract 75N91022F00030?
75N91022F00030 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 23, 2022.
How much is contract 75N91022F00030 worth?
The government has obligated $6,232,704 on 75N91022F00030.
Is contract 75N91022F00030 an order under another contract?
Yes. 75N91022F00030 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00030 competed?
The extent of competition for 75N91022F00030 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award